Trial Profile
An Observer-blind, Dose Ranging Safety and Immunogenicity Study of GSK Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus H5N1 vaccines (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 19 Jul 2021 Results published in the Pediatric Infectious Disease Journal
- 24 Apr 2018 Status changed from active, no longer recruiting to completed.
- 09 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Feb 2018.